"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
Targeting AXL in mesothelioma: From functional characterization to clinical implication. Crit Rev Oncol Hematol. 2023 Aug; 188:104043.
-
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May; 15(6):569-79.
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12; 369(11):1023-34.
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 01; 28(31):4697-705.
-
Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol. 2000 Apr; 15(4):357-68.
-
c-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res. 1991 Mar-Apr; 11(2):921-4.
-
Expression of c-erbA in human hepatocellular carcinomas. Anticancer Res. 1989 Jul-Aug; 9(4):885-7.